Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Freres, Pierre
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma	Active, not recruiting	2	256	Europe, Canada, US, RoW	Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics	Locally Advanced or Metastatic Urothelial Carcinoma	01/25	01/25
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM	Active, not recruiting	N/A	982	Europe, Canada, Japan, US, RoW	Optune®	NovoCure Ltd.	Glioblastoma Multiforme	01/26	01/26
PRIMALung, NCT04790253: PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients ( Study)	Recruiting	N/A	600	Europe	Prophylactic cranial irradiation	European Organisation for Research and Treatment of Cancer - EORTC, UNICANCER	Limited Stage Small Cell Lung Cancer, Extensive-stage Small-cell Lung Cancer	04/28	04/28